To see this page, please, enable javaScript and styleSheets on your browser: Tools -> Internet Options ...
Reload !
Gene ATG2ATABLE OF CONTENTS / OPEN CLOSE ALL PARAGRAPHS
Summary back to top
Compact gene diagram back to top
131 supporting clones for gene ATG2A back to top
cDNA accession
Links to the sequence
Tissue

most 5' clones
in red
Match
mRNA
From bp
to bp
in mRNA
From bp
to bp
in accs.
Clone encodes
complete protein
(with AA variation)
Features Anomalies
detected by
AceView
Accession
match over
(% length)
Base differences
relative to genome
(% identity)
BC110650 Skin, melanotic melanoma. .a 1 to 6358 1 to 6358 P656R A1286S tiling clone, AAA Possibly primed on the genome, locally A rich (14/16 A in genome downstream of last aligned base) 6358/6358
(100 %)
4 diff
(100.0 %id)
NM_015104.2   .a 1 to 6378 1 to 6378 exact RefSeq,   6378/6378
(100 %)
5 diff
(100.0 %id)
BU166319 melanotic melanoma, skin .a 3 to 846 1 to 853       853/861
(99 %)
17 diff
(98.1 %id)
BM146359 leukopheresis .a 41 to 369 1 to 330       330/339
(97 %)
18 diff
(94.7 %id)
BE247267 leukopheresis .a 41 to 531 1 to 491       491/491
(100 %)
8 diff
(98.4 %id)
AK307684 thymus .a 42 to 2287 1 to 2246       2246/2249
(99 %)
5 diff
(99.8 %id)
CB959929 Human Placenta, placenta .a 42 to 685 28 to 677       650/813
(79 %)
15 diff
(98.2 %id)
DC388235 small intestine .a 42 to 615 1 to 574       574/574
(100 %)
0 diff
(100 %id)
DC405415 thymus .a 42 to 613 1 to 572       572/572
(100 %)
1 diff
(99.9 %id)
DC405837 thymus .a 42 to 616 1 to 575       575/575
(100 %)
0 diff
(100 %id)
AB007864 brain .a 60 to 6358 1 to 6299 P656R tiling clone, available from KIAA,   6299/6299
(100 %)
2 diff
(100.0 %id)
AW827063 hepatic adenoma, Liver .a 61 to 505 1 to 444       444/444
(100 %)
1 diff
(99.8 %id)
BQ057657 lymph, lymphoma, cell line .a 63 to 939 1 to 879   tiling clone,   879/992
(88 %)
5 diff
(99.5 %id)
BQ062212 lymph, lymphoma, cell line .a 63 to 447 1 to 392   available from MGC,   392/1071
(36 %)
11 diff
(99.0 %id)
BQ064111 lymph, lymphoma, cell line .a 63 to 893 1 to 839       837/1040
(80 %)
9 diff
(99.2 %id)
BQ066013 lymph, lymphoma, cell line .a 63 to 893 1 to 838       838/995
(84 %)
7 diff
(99.3 %id)
CN314360 embryonic stem cells, cell lines H1, H7, andH9 .a 1894 to 2568 1 to 676       676/676
(100 %)
4 diff
(99.5 %id)
BI036200 nervous_tumor .a 2356 to 2612 1 to 256       256/397
(64 %)
6 diff
(98.5 %id)
EC575634 Prostate .a 2620 to 2722 108 to 5       104/109
(95 %)
0 diff
(100 %id)
BX283921 astrocytoma grade IV, cell line, brain .a 2977 to 3475 1 to 499       499/499
(100 %)
1 diff
(99.8 %id)
BM856383 stomach .a 3255 to 3850 1 to 596       596/596
(100 %)
1 diff
(99.9 %id)
BG386523 adenocarcinoma cell line, colon .a 3455 to 3846 1 to 392       392/554
(70 %)
2 diff
(99.7 %id)
CV355808 bladder_tumor .a 3549 to 3755 1 to 208       208/213
(97 %)
18 diff
(91.6 %id)
BQ361691 ovary .a 3645 to 3857 4 to 228       235/238
(98 %)
57 diff
(76.1 %id)
BM912902 amelanotic melanoma, cell line, skin .a 3717 to 4219 1 to 505       505/1270
(39 %)
18 diff
(98.6 %id)
BM915672 amelanotic melanoma, cell line, skin .a 3717 to 4571 1 to 871       871/1032
(84 %)
22 diff
(97.9 %id)
BM549748 leukocyte .a 3939 to 4787 20 to 872       853/1068
(79 %)
27 diff
(97.5 %id)
AA322923 brain, cerebellum .a 4021 to 4325 1 to 306       306/306
(100 %)
6 diff
(98.1 %id)
AA323053 brain, cerebellum .a 4021 to 4349 1 to 332       332/340
(97 %)
10 diff
(97.1 %id)
EL594822 epidermis, skin .a 4034 to 4172 14 to 152       139/166
(83 %)
11 diff
(93.4 %id)
BF345759 anaplastic oligodendroglioma with 1p/19qloss, brain .a 4070 to 4817 1 to 738       740/828
(89 %)
14 diff
(98.4 %id)
BY796540 eye .a 4092 to 4733 1 to 642       642/642
(100 %)
0 diff
(100 %id)
BF984155 duodenal adenocarcinoma, cell line, small intestine .a 4165 to 4889 1 to 724       724/1131
(64 %)
4 diff
(99.7 %id)
BE254933 eye, retinoblastoma .a 4202 to 4867 1 to 663       663/783
(84 %)
9 diff
(98.9 %id)
CD671341 eye, Iris .a 4308 to 4927 1 to 620       620/620
(100 %)
0 diff
(100 %id)
BF688367 eye, normal pigmented retinal epithelium .a 4320 to 5039 1 to 712       712/714
(99 %)
14 diff
(98.1 %id)
BC008593 Cervix, carcinoma .a 4373 to 6358 1 to 1986   available from MGC, AAA Possibly primed on the genome, locally A rich (14/16 A in genome downstream of last aligned base) 1986/1986
(100 %)
0 diff
(100 %id)
BE547100 cervical carcinoma cell line, cervix .a 4394 to 4973 1 to 584   available from MGC,   584/793
(73 %)
9 diff
(98.9 %id)
BE543967 cervical carcinoma cell line, cervix .a 4530 to 5146 1 to 620       620/620
(100 %)
13 diff
(98.0 %id)
AA299540 uterus .a 4592 to 4841 1 to 250       250/250
(100 %)
4 diff
(98.4 %id)
BQ946653 epidermoid carcinoma, cell line, lung .a 4594 to 5383 1 to 793       793/975
(81 %)
16 diff
(98.4 %id)
BQ063777 lymph, lymphoma, cell line .a 4608 to 5387 1 to 790       790/1090
(72 %)
18 diff
(98.4 %id)
BE246119 leukopheresis .a 4612 to 4985 375 to 1       375/375
(100 %)
3 diff
(99.2 %id)
BI115021 muscle, rhabdomyosarcoma .a 4617 to 5481 1 to 851       851/877
(97 %)
29 diff
(96.7 %id)
BF316533 brain, neuroblastoma .a 4689 to 5332 1 to 633       631/925
(68 %)
16 diff
(98.3 %id)
EC525810 Prostate .a 4720 to 4806 1 to 87       87/87
(100 %)
0 diff
(100 %id)
BX283218 brain, neuroblastoma, cell line .a 4755 to 5137 1 to 385       385/397
(96 %)
4 diff
(99.0 %id)
BQ071019 brain, neuroblastoma, cell line .a 4757 to 5632 1 to 888       888/964
(92 %)
23 diff
(97.7 %id)
CX753872 Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass .a 4763 to 5539 1 to 769     Submitted on the opposite strand 769/829
(92 %)
9 diff
(99.0 %id)
BG977790 colon_ins .a 4781 to 5363 8 to 593       592/595
(99 %)
34 diff
(94.3 %id)
CB216526 normal endometrium, mid-secretory phase,cycle day 23, uterus .a 4808 to 5445 1 to 638       638/638
(100 %)
0 diff
(100 %id)
CB268592 adipose .a 4825 to 5049 1 to 223       223/225
(99 %)
4 diff
(98.3 %id)
BM554945 amelanotic melanoma, cell line, skin .a 4853 to 5553 1 to 704       704/1125
(62 %)
13 diff
(98.9 %id)
CU443512 epidermis .a 4906 to 5373 486 to 19     Submitted on the opposite strand 468/486
(96 %)
4 diff
(99.2 %id)
BC033850 Kidney, hypernephroma .a 4953 to 6358 12 to 1417   available from MGC, AAA Possibly primed on the genome, locally A rich (14/16 A in genome downstream of last aligned base) 1406/1406
(100 %)
0 diff
(100 %id)
BG165737 hypernephroma, cell line, Kidney .a 4954 to 5695 1 to 747   available from MGC,   747/1291
(57 %)
34 diff
(97.4 %id)
CA455003   .a 4982 to 5878 1 to 912       912/912
(100 %)
21 diff
(97.7 %id)
BG177768 lymph, lymphoma, cell line .a 5035 to 5660 1 to 633       633/1171
(54 %)
33 diff
(97.2 %id)
BE736048 adenocarcinoma, Pancreas .a 5067 to 5868 1 to 808       808/867
(93 %)
35 diff
(96.0 %id)
BQ672675 epidermoid carcinoma, cell line, salivary gland .a 5106 to 5690 1 to 585       585/988
(59 %)
6 diff
(99.4 %id)
CB269629 adipose .a 5362 to 5944 1 to 584       584/584
(100 %)
1 diff
(99.9 %id)
BX283573 eye, retinoblastoma .a 5404 to 5905 1 to 502       502/502
(100 %)
1 diff
(99.9 %id)
BG471738 eye, retinoblastoma .a 5404 to 6192 1 to 790       790/791
(99 %)
13 diff
(98.4 %id)
BC027481 Cervix, carcinoma .a 5434 to 6358 1 to 925   available from MGC, AAA Possibly primed on the genome, locally A rich (14/16 A in genome downstream of last aligned base) 925/925
(100 %)
0 diff
(100 %id)
CD672001 eye, Iris .a 5443 to 6008 1 to 566       566/566
(100 %)
5 diff
(99.2 %id)
BF345510 anaplastic oligodendroglioma with 1p/19qloss, brain .a 5464 to 6269 1 to 792       792/962
(82 %)
28 diff
(97.1 %id)
BI816709 anaplastic oligodendroglioma with 1p/19qloss, brain .a 5464 to 6130 1 to 668       668/668
(100 %)
9 diff
(98.7 %id)
BU931984 ovary, teratocarcinoma, cell line .a 5531 to 6346 821 to 1     Submitted on the opposite strand 821/912
(90 %)
16 diff
(98.3 %id)
BF688845 eye, normal pigmented retinal epithelium .a 5550 to 6328 782 to 13       770/1013
(76 %)
14 diff
(98.7 %id)
AV700614 hepatocellular carcinoma .a 5568 to 6338 771 to 1       771/797
(96 %)
22 diff
(97.3 %id)
TI_149315156   .a 5572 to 6358 839 to 73   AAA Possibly primed on the genome, locally A rich (14/16 A in genome downstream of last aligned base) 767/978
(78 %)
40 diff
(96.0 %id)
TI_159702884   .a 5630 to 6359 848 to 129       720/1044
(68 %)
9 diff
(99.2 %id)
BP429809   .a 5651 to 6013 1 to 363       363/363
(100 %)
3 diff
(99.2 %id)
BM680420 eye, fetal eye .a 5679 to 6358 698 to 19   AAA Possibly primed on the genome, locally A rich (14/16 A in genome downstream of last aligned base) 680/680
(100 %)
2 diff
(99.8 %id)
CA432115 cell lines, Enchondroma .a 5679 to 6358 698 to 19   AAA Possibly primed on the genome, locally A rich (14/16 A in genome downstream of last aligned base) 680/680
(100 %)
1 diff
(99.9 %id)
TI_149302714   .a 5702 to 6358 725 to 69   AAA Possibly primed on the genome, locally A rich (14/16 A in genome downstream of last aligned base) 657/980
(67 %)
0 diff
(100 %id)
BM980863 lung, Primary Lung Cystic Fibrosis EpithelialCells .a 5702 to 6358 675 to 19   AAA Possibly primed on the genome, locally A rich (14/16 A in genome downstream of last aligned base) 657/665
(98 %)
0 diff
(100 %id)
BQ186169 eye, fetal eyes, lens, eye anterior segment,optic nerve, retina, Retina Foveal and Macular, RPE andChoroid .a 5702 to 6082 1 to 381       381/384
(99 %)
3 diff
(99.3 %id)
TI_151731062   .a 5702 to 6090 443 to 55       389/1051
(37 %)
0 diff
(100 %id)
AW168132 serous papillary carcinoma, high grade, 2pooled tumors, uterus .a 5735 to 6359 630 to 4       627/630
(99 %)
0 diff
(100 %id)
AW468262 myeloid cells, 18 pooled CML cases, BCR/ABLrearrangement positive, includes both chronic phase andmyeloid blast crisis, whole blood .a 5753 to 6352 619 to 20   AAA   600/606
(99 %)
0 diff
(100 %id)
CA438660 lung, Metastatic Chondrosarcoma .a 5766 to 6362 614 to 19   AAA Possibly primed on the genome, locally A rich (14/16 A in genome downstream of last aligned base) 596/596
(100 %)
7 diff
(98.9 %id)
CF138621 lymph .a 5794 to 6264 1 to 471       471/471
(100 %)
5 diff
(99.0 %id)
TI_154168638   .a 5800 to 6270 94 to 564       471/871
(54 %)
1 diff
(99.9 %id)
BM174933 hippocampus .a 5813 to 6120 14 to 322       309/367
(84 %)
21 diff
(94.3 %id)
AI800743 pooled .a 5822 to 6358 556 to 29   AAA Possibly primed on the genome, locally A rich (14/16 A in genome downstream of last aligned base) 528/533
(99 %)
0 diff
(100 %id)
BM711492 eye, optic nerve .a 5830 to 6359 1 to 530       530/531
(99 %)
1 diff
(99.9 %id)
AW149412 brain, medulloblastoma .a 5842 to 6359 525 to 7       519/526
(98 %)
0 diff
(100 %id)
BM855676 stomach .a 5846 to 6189 1 to 344       344/344
(100 %)
0 diff
(100 %id)
AI920829 uterus, well-differentiated endometrialadenocarcinoma, 7 pooled tumors .a 5855 to 6358 546 to 43   AAA Possibly primed on the genome, locally A rich (14/16 A in genome downstream of last aligned base) 504/504
(100 %)
38 diff
(92.5 %id)
CN479238 lung, Primary Lung Cystic Fibrosis EpithelialCells .a 5857 to 6358 519 to 19   AAA Possibly primed on the genome, locally A rich (14/16 A in genome downstream of last aligned base) 501/501
(100 %)
5 diff
(99.1 %id)
AI638563 uterus, well-differentiated endometrialadenocarcinoma, 7 pooled tumors .a 5885 to 6373 495 to 6       490/537
(91 %)
0 diff
(100 %id)
AI263391 mixed (see below), Pooled human melanocyte, fetal heart, andpregnant uterus .a 5902 to 6359 460 to 3       458/460
(99 %)
0 diff
(100 %id)
BU732394 eye, optic nerve .a 5904 to 6352 472 to 25   AAA   448/460
(97 %)
0 diff
(100 %id)
TI_151769737   .a 5907 to 6268 97 to 457       361/1568
(23 %)
2 diff
(99.9 %id)
AI751079 Bone, Hip .a 5933 to 6358 11 to 437       427/443
(96 %)
6 diff
(98.7 %id)
AI751080 Bone, Hip .a 5933 to 6358 432 to 7       426/455
(93 %)
0 diff
(100 %id)
AW131183 poorly differentiated adenocarcinoma withsignet ring cell features, stomach .a 5989 to 6359 378 to 7       372/378
(98 %)
0 diff
(100 %id)
AI251827 brain, tumor, 5 pooled (see description) .a 6000 to 6359 367 to 8       360/367
(98 %)
0 diff
(100 %id)
AA548754 normal prostate, Prostate .a 6006 to 6358 367 to 16   AAA Possibly primed on the genome, locally A rich (14/16 A in genome downstream of last aligned base) 352/352
(100 %)
1 diff
(99.8 %id)
AA576709 colon, colon tumor RER+ .a 6009 to 6359 357 to 8       350/357
(98 %)
0 diff
(100 %id)
AA665727   .a 6026 to 6299 281 to 8       274/281
(97 %)
0 diff
(100 %id)
AF001545   .a 6029 to 6358 1 to 332   AAA Possibly primed on the genome, locally A rich (14/16 A in genome downstream of last aligned base) 332/332
(100 %)
4 diff
(98.8 %id)
AA909788 pooled germ cell tumors .a 6050 to 6358 322 to 15   AAA Possibly primed on the genome, locally A rich (14/16 A in genome downstream of last aligned base) 308/308
(100 %)
1 diff
(99.7 %id)
AW339554 myeloid cells, 18 pooled CML cases, BCR/ABLrearrangement positive, includes both chronic phase andmyeloid blast crisis, whole blood .a 6052 to 6358 307 to 1       307/307
(100 %)
0 diff
(100 %id)
EC441617 Prostate .a 6121 to 6232 16 to 123       108/123
(87 %)
6 diff
(95.2 %id)
AA875953 2 pooled tumors (clear cell type), Kidney .a 6136 to 6359 229 to 6       224/229
(97 %)
0 diff
(100 %id)
BE300485 choriocarcinoma, placenta .a 6183 to 6352 186 to 17   AAA   170/176
(96 %)
0 diff
(100 %id)
BI519808 leukocyte .a 6202 to 6285 87 to 3       85/87
(97 %)
0 diff
(100 %id)
AI682030 serous papillary carcinoma, high grade, 2pooled tumors, uterus .a 6225 to 6359 137 to 3       135/137
(98 %)
0 diff
(100 %id)
CR989726 T-Lymphocytes .b 1 to 861 1 to 863   tiling clone,   863/863
(100 %)
2 diff
(99.8 %id)
AW500152 lymph .b 101 to 474 8 to 381       374/381
(98 %)
1 diff
(99.8 %id)
TI_154154314   .b 101 to 563 80 to 543       464/660
(70 %)
13 diff
(98.1 %id)
BM454673 embryonal carcinoma, cell line, testis .b 565 to 1509 1 to 948       948/1037
(91 %)
16 diff
(98.5 %id)
BM560754 astrocytoma grade IV, cell line, brain .b 590 to 1505 1 to 922       922/1057
(87 %)
16 diff
(98.5 %id)
BU182094 eye, retinoblastoma .b 746 to 1509 1 to 767   tiling clone,   767/863
(88 %)
13 diff
(98.5 %id)
BC053596 Brain, hippocampus .b 1290 to 3975 1 to 2686   tiling clone, available from MGC, AAA Possibly primed on the genome, locally A rich (14/16 A in genome downstream of last aligned base) 2686/2686
(100 %)
0 diff
(100 %id)
BM561384 amelanotic melanoma, cell line, skin .b 1345 to 2150 11 to 830       820/1094
(74 %)
26 diff
(97.7 %id)
CR993170 T-Lymphocytes .b 1492 to 2030 1 to 539       539/542
(99 %)
1 diff
(99.9 %id)
AK300925 small intestine .c 1 to 833 5 to 837   tiling clone,   837/837
(100 %)
0 diff
(100 %id)
AK126181 thymus .d 1 to 2030 2 to 2031   tiling clone, available from FLJ,   2031/2031
(100 %)
3 diff
(99.9 %id)
DB129712 thymus .d 1 to 574 2 to 575   capped   574/575
(99 %)
2 diff
(99.7 %id)
DB344494 thymus .d 1502 to 2030 529 to 1       529/537
(98 %)
1 diff
(99.9 %id)
AI699039 uterus, well-differentiated endometrialadenocarcinoma, 7 pooled tumors .e 1 to 493 494 to 1 S2F H11Q H14Q V15A T16R ... tiling clone,   494/494
(100 %)
10 diff
(98.0 %id)
AW089744 ovary, tumor, 5 pooled (see description) .e 13 to 357 345 to 1   tiling clone,   345/345
(100 %)
4 diff
(98.9 %id)
AI687752 poorly-differentiated endometrialadenocarcinoma, 2 pooled tumors, uterus .e 31 to 515 485 to 1   tiling clone,   485/485
(100 %)
3 diff
(99.4 %id)
BU951730 Pancreas, Purified pancreatic islet .e 66 to 513 1 to 448   tiling clone,   448/448
(100 %)
0 diff
(100 %id)
BQ326903 colon_normal .f-u 1 to 381 1 to 384 W3C S4I A5R G6R R7K ... tiling clone,   384/384
(100 %)
12 diff
(96.9 %id)
AA082774   Gene ATG2A, variant not shown         Submitted on the opposite strand    
AA085419   Gene ATG2A, variant not shown         Submitted on the opposite strand    
BE294981 muscle, rhabdomyosarcoma Gene ATG2A, variant not shown         This clone was ignored    
BM802722 embryonal carcinoma, cell line, testis Gene ATG2A, variant not shown         This clone was ignored    
BC113090 PCR rescued clones Gene ATG2A, variant not shown         Suspected internal deletion, this clone was ignored    
BC113091 PCR rescued clones Gene ATG2A, variant not shown         Suspected internal deletion, this clone was ignored    
? Gene Summary Gene on genome mRNA:.a, .b, .c, .d, .e, .f-u Alternative mRNAs features, proteins, introns, exons, sequences Expression Tissue Function, regulation, related genes CI